Immuron (ASX:IMC) Strengthens Growth Story with IMM-529 Advancing to Phase 2

Highlights

• Immuron combines commercial products and pipeline assets around an oral antibody platform.
• IMM-529 is advancing toward Phase 2 following FDA approval of its investigational new drug application and initiation of a partnering process..
• The therapy targets recurrent CDI through a differentiated three-target mechanism.
• Immuron reported sales growth across major markets in the March 2026 period.
• Partnering to progress clinical activity keep IMM-529 central to the company narrative.

Immuron Limited (ASX:IMC) has built its story around a combination of commercial-stage gastrointestinal health products and a clinical pipeline targeting infectious diseases, with its oral polyclonal antibody platform linking both sides of the business. Products including Travelan® and ProIBS provide an established commercial base, while pipeline candidates such as IMM-529 reflect the company’s strategic focus on expanding therapeutic applications through targeted antibody technology.  

Within this broader framework of steady product revenues and advancing pipeline development, IMM-529 has emerged as a key value driver. As the candidate progresses toward Phase 2 evaluation in recurrent Clostridioides difficile infection (CDI), it is increasingly shaping Immuron’s forward-looking development story.  

Commercial Platform and Pipeline Depth

Immuron’s broader strategy rests on a platform designed to generate orally active polyclonal antibodies capable of acting directly in the gastrointestinal tract. The company’s technology is intended to target pathogens and toxins while also preventing their adhesion to the gut wall, supporting both commercial and pipeline applications.

This platform underpins existing marketed products while also supporting clinical assets under development.

IMM-529 Moves Toward Phase 2

IMM-529 gained a significant regulatory milestone when the U.S. Food and Drug Administration approved the company’s Investigational New Drug application in November last year. This approval paves the way for a Phase 2 clinical trial. Immuron has indicated plans to partner this asset to advance clinical development and commercialisation.

The candidate is being developed as an adjunctive therapy in combination with standard-of-care antibiotics for preventing and treating recurrent CDI. Its positioning reflects a response to a treatment setting where recurrence remains a persistent challenge.

A Differentiated Three-Target Approach

IMM-529 is designed to target three virulence components of C. difficile — Toxin B, spores and surface layer proteins of vegetative cells. Developed using hyperimmune bovine colostrum-derived antibodies, the therapy is designed around a multi-target mechanism intended to address infection while supporting faster restoration of normal gut flora.

Pre-clinical models cited by the company have shown outcomes linked to prevention of primary disease and protection against recurrence, forming part of the rationale for advancing into Phase 2 trials.

Significant Market Opportunity

The opportunity for IMM-529 is framed against the scale of recurrent CDI, which remains one of the leading healthcare-associated infections in the United States. With recurrence rates rising after multiple episodes and severe disease linked to significant complications, the treatment landscape continues to attract interest in advanced therapeutic options.

Immuron estimates that C. difficile causes approximately 400,000 cases and 30,000 deaths annually in the U.S. The company has identified a total addressable market of approximately USD 3.52 billion for recurrent CDI, positioning IMM-529 within a sizeable and clinically relevant market segment.

Financial Performance Adds Commercial Context

Alongside pipeline progress, Immuron’s recent sales performance provides additional commercial context to its broader growth strategy.

Immuron reported global third-quarter sales of AUD 1.5 million, up 16% on the prior comparative period, while year-to-date March 2026 sales reached AUD 5.7 million, up 7%. Australian year-to-date sales rose 14% to AUD 4.2 million, while U.S. year-to-date sales increased 10% to AUD 1.3 million. Canada also recorded quarterly growth, including initial sales through Jean Coutu in Quebec.

These figures place financial performance alongside pipeline advancement, highlighting the commercial base supporting the company’s development strategy.

With FDA IND approval secured, Phase 2 preparations underway and a differentiated mechanism targeting a large unmet need, IMM-529 is becoming central to Immuron’s next phase of development. As the partnering progress continues, the program is likely to remain a key focus in evaluating the company’s potential.

IMC shares traded at AUD 0.029 on 29 April 2026.